Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroblastoma 1Medulloblastoma 1Familial ependymoma 1Choroid Plexus Neoplasms 1Carcinoma, Medullary 1Astrocytoma 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 10Paclitaxel 7Iodine-131 6Fluorodeoxyglucose F18 6Sorafenib 5vandetanib 4trametinib 4selpercatinib 4dabrafenib 4pembrolizumab 3fosbretabulin 3cabozantinib 3Vemurafenib 3Sunitinib 3Specimen Handling 3Nivolumab 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2romidepsin 2pazopanib 2lenvatinib 2combretastatin 2Trastuzumab 2Thyrotropin Alfa 2Ipilimumab 2Gefitinib 2FAPI-46 2Everolimus 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Vorinostat × Endocrine × Clear all
NCT00134043 2014-08-11

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡